Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company's lead product candidate is KRRO-121 for the treatment for hyperammonemia. It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe drug-associated anesthetics, and other pain indications. Korro Bio, Inc. has a collaboration agreement with Novo Nordisk A/S to treat cardiometabolic diseases. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.…
Korro to Participate in Upcoming Investor Conferences
Korro Bio (NASDAQ: KRRO) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 58 employees.
The shares were at 12.18 USD on 20 November 2026, down 64.0% over 52 weeks. Its 52-week range is 5.204 USD to 36.79 USD: the price is 66.9% below the high and 134.1% above the low.
Its market capitalisation is 167.18M USD.
Korro Bio reports return on equity of -228.0%.
It holds more cash than debt, a net cash position of 63.47M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 10 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 21.50 USD is 76.5% above the current price. The next earnings report is expected on 11 March 2027.